EVERSANA and Waltz Health Merge to Transform Drug Commercialization

EVERSANA and Waltz Health have unveiled a $6 billion merger that promises to reshape how pharmaceutical companies bring drugs to market and connect with patients. The combined entity merges Waltz Health's software-powered drug-price marketplaces and direct-to-payer model with EVERSANA's established global commercialization services, creating what the companies describe as a next-generation approach to drug access and value in the U.S. healthcare system.

The merger addresses critical challenges in pharmaceutical commercialization, particularly for high-cost drug classes like GLP-1s. EVERSANA brings its position as a leader in pharma commercialization, serving the top 50 pharmaceutical and biotech companies globally. Waltz Health contributes its technology platform featuring AI-powered prescription routing and affordability solutions that connect patients, health insurers, self-insured employers, governments, and pharmacy benefit managers.

The combined organization will offer life sciences companies direct connections to payers while providing comprehensive reach and execution capabilities across multiple domains. In pharma commercialization, the merger integrates patient services, field teams, digital marketing, reimbursement support, and real-world evidence, all supported by modern software infrastructure. Through Waltz's direct-to-payer and direct-to-patient solutions, the EVERSANA COMPLETE Commercialization™ model gains channels to reach millions of covered lives.

The unified platform enables net-price models, copay optimization, and integrated pharmacy routing to reduce patient abandonment and increase therapeutic persistence. Additionally, through Waltz Connect, EVERSANA now operates a fully integrated, URAC-accredited specialty pharmacy network designed for high-cost and limited distribution drugs.

Mark Thierer, Co-founder and CEO of Waltz Health and Chairman of EVERSANA, will lead the combined organization as CEO. "This is a pivotal moment for the healthcare industry," said Thierer. "By combining EVERSANA's pharma services with Waltz's technology-enabled payer solutions, we're creating a unified platform that connects life sciences innovation directly to the organizations and individuals we're meant to serve. This model is built to accelerate access, improve outcomes and deliver smarter, more transparent drug commercialization at every step."

The merger represents a strategic response to evolving healthcare market dynamics where traditional commercialization models face increasing pressure to demonstrate value while ensuring patient access to innovative therapies.

Click here for the original news story.